FDA NDC Directory
Recently listed NDCs
Finished products in the FDA NDC Directory with the newest marketing start dates — new brands and generics, and new strengths or packages of existing products.
A listing is not an approval
The date shown is the marketing start date the labeler reported. Many new listings are generics, repackaged or relabeled products, or new package sizes. The marketing category (NDA, ANDA, BLA) on each product page says under what authority it is marketed.
Newest first
831 listings in the last 90 days
| Product | Strength | Form · route | Labeler | Listed | Product NDC |
|---|---|---|---|---|---|
| Bupropion Hydrochloride (XL)bupropion hydrochloride | Bupropion hydrochloride 300 mg/1 | Tablet, Film coated, Extended releaseOral | Preferred Pharmaceuticals Inc. | Jul 24, 2026 | 68788-4172 |
| Clopidogrelclopidogrel bisulfate | Clopidogrel bisulfate 75 mg/1 | Tablet, Film coatedOral | Preferred Pharmaceuticals Inc. | Jul 24, 2026 | 68788-4173 |
| ziprasidone | Ziprasidone hydrochloride 80 mg/1 | CapsuleOral | REMEDYREPACK INC. | Jul 24, 2026 | 70518-4709 |
| Garzulysinsulin aspart-fsan | Insulin aspart 100 [iU]/mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | Jul 24, 2026 | 71288-903 |
| Garzulysinsulin aspart-fsan | Insulin aspart 100 [iU]/mL | Injection, SolutionIntravenous, Subcutaneous | Meitheal Pharmaceuticals Inc. | Jul 24, 2026 | 71288-904 |
| Insulin Diluting Medium for Garzulyswater injection | Water 1 mL/mL | Injection, SolutionIntravenous, Subcutaneous | Meitheal Pharmaceuticals Inc. | Jul 24, 2026 | 71288-909 |